Nicole Hartmann, PA
Physician Assistant · Las Vegas, NVNPI 1225306343
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 384 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Among physician assistant clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 384 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$780
- Johnson & Johnson$629
- AbbVie$490
- Neurocrine Biosciences, Inc.$479
- plus $2K from 17 others
What the payments were for
- Food & beverage$7,069100%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 71 | $1,288 |
| Alkermes, Inc. | 45 | $1,071 |
| Otsuka America Pharmaceutical, Inc. | 51 | $780 |
| Johnson & Johnson | 27 | $629 |
| AbbVie | 31 | $490 |
| Neurocrine Biosciences, Inc. | 30 | $479 |
| E.r. Squibb & Sons, L.L.C. | 25 | $397 |
| Vanda Pharmaceuticals Inc. | 16 | $384 |
| Sunovion Pharmaceuticals Inc. | 15 | $218 |
| Lundbeck LLC | 11 | $197 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $182 |
| Avanir Pharmaceuticals, Inc. | 9 | $178 |
| Almatica Pharma LLC | 9 | $163 |
| Axsome Therapeutics, Inc. | 5 | $104 |
| Teva Pharmaceuticals USA, Inc. | 4 | $87 |
| Eisai Inc. | 4 | $74 |
| Supernus Pharmaceuticals, Inc. | 5 | $70 |
| Indivior Inc. | 3 | $67 |
| Sage Therapeutics, LLC | 4 | $57 |
| Corium, LLC | 4 | $56 |
| Bausch Health US, LLC | 3 | $56 |
| Tris Pharma Inc | 2 | $49 |
| Neuronetics, Inc. | 1 | $16 |
How this compares
$7,092 in reported general payments places this provider in the 90th percentile of 881 physician assistant providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 41 | $336,775 |
| Invega SustennaPaliperidone Palmitate | 74 | $230,768 |
| AustedoDeutetrabenazine | 13 | $166,980 |
| VraylarCariprazine Hcl | 39 | $62,904 |
| RexultiBrexpiprazole | 38 | $62,126 |
| Abilify MaintenaAripiprazole | 20 | $57,370 |
| CaplytaLumateperone Tosylate | 17 | $30,922 |
| BelsomraSuvorexant | 35 | $15,392 |
| TrintellixVortioxetine Hydrobromide | 17 | $12,059 |
| Fluphenazine Hcl | 23 | $10,278 |
| Quetiapine Fumarate | 656 | $9,002 |
| Hydroxyzine Hcl | 277 | $7,894 |
| Lurasidone Hcl | 46 | $6,897 |
| AdderallDextroamphetamine/Amphetamine | 11 | $6,729 |
| Aripiprazole | 228 | $6,483 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $479 | $336,77541 claims |
| Johnson & JohnsonInvega Sustenna | $629 | $230,76874 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $87 | $166,98013 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $780 | $119,49558 claims |
| AbbVieVraylar | $490 | $62,90439 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,288 | $30,92217 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Adderall, Vyvanse | $182 | $23,32240 claims |
| Almatica Pharma LLCSertraline Hcl | $163 | $2,112419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 881 physician assistant providers in Nevada.
Other physician assistant in Las Vegas
- Steven HawkesLas Vegas$70K
- Nathan MorganLas Vegas$44K
- Stephanie DastrupLas Vegas$23K
- Sandra OviedoLas Vegas$21K
- Patrick JamesonLas Vegas$20K
- Jordan ChristensenLas Vegas$19K
- Jacquelyn DaneshforouzLas Vegas$18K
- Violet AmirjalaliLas Vegas$15K
- Joseph GuruleLas Vegas$15K
- Rebecca Markin-NewsomeLas Vegas$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.